Free Trial
NASDAQ:EVOK

Evoke Pharma (EVOK) Stock Price, News & Analysis

Evoke Pharma logo
$5.17 -0.01 (-0.19%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$5.23 +0.06 (+1.16%)
As of 09/12/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Evoke Pharma Stock (NASDAQ:EVOK)

Key Stats

Today's Range
$5.10
$5.23
50-Day Range
$2.65
$6.99
52-Week Range
$1.94
$12.32
Volume
19,619 shs
Average Volume
437,115 shs
Market Capitalization
$8.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evoke Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
3rd Percentile Overall Score

EVOK MarketRank™: 

Evoke Pharma scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Evoke Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evoke Pharma is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evoke Pharma is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Evoke Pharma has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Evoke Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    7.63% of the float of Evoke Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Evoke Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evoke Pharma has recently increased by 79.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Evoke Pharma does not currently pay a dividend.

  • Dividend Growth

    Evoke Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.63% of the float of Evoke Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Evoke Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evoke Pharma has recently increased by 79.52%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Evoke Pharma has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Evoke Pharma this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for EVOK on MarketBeat in the last 30 days.
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVOK Stock News Headlines

Evoke Pharma (NASDAQ:EVOK) Upgraded to Hold at Wall Street Zen
Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Headlines

EVOK Stock Analysis - Frequently Asked Questions

Evoke Pharma's stock was trading at $4.42 at the beginning of the year. Since then, EVOK shares have increased by 17.0% and is now trading at $5.17.

Evoke Pharma, Inc. (NASDAQ:EVOK) released its quarterly earnings results on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.32. The specialty pharmaceutical company had revenue of $3.75 million for the quarter, compared to the consensus estimate of $3.80 million. Evoke Pharma had a negative trailing twelve-month return on equity of 99.48% and a negative net margin of 42.07%.

Evoke Pharma shares reverse split on the morning of Thursday, August 1st 2024.The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
8/14/2025
Today
9/12/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EVOK
CIK
1403708
Fax
N/A
Employees
4
Year Founded
2007

Profitability

EPS (Trailing Twelve Months)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.35 million
Net Margins
-42.07%
Pretax Margin
-42.07%
Return on Equity
-99.48%
Return on Assets
-33.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.37
Quick Ratio
1.32

Sales & Book Value

Annual Sales
$10.25 million
Price / Sales
0.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.74 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
1,560,000
Free Float
1,523,000
Market Cap
$8.07 million
Optionable
Not Optionable
Beta
-0.13

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:EVOK) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners